Near-normalization of hyperglycemia through 4 weeks of insulin therapy [173], or through administration of sulphonylurea [174] or DPP4 inhibitor [175] improves the insulinotropic effect of GIP in people living with T2D, supporting that GIPR agonism may offer pharmacological benefits on glucose control when given together with drugs that decrease hyperglycemia. The gene discussed is GIP; the disease is Hyperglycemia.